Avci et al. [36] found that co-treatment of glioblastoma cells with an NF-κB inhibitor that inhibits TNFα-induced IκBα phosphorylation—BAY 11–7082 and alkylating agent Temozolomide resulted in significant reduction in cell viability, suppressed NF-κB signaling, and enhanced apoptosis via actin skeleton modulation (Fig. 4). Here, NFKB1 is linked to glioblastoma.